Department of Research, Ukrainian Academy of Biological Medicine, Kiev, Ukraine, Department of Internal Medicine, Ukrainian Medical Dental Academy, Poltava, UkraineBackground: In the treatment of inflammation, the action of widely used non-steroidal anti-inflammatory drugs (NSAIDs) is directed mainly to inhibit
the synthesis of proinflammatory mediators, cell migration and proliferation, as well as to stimulate the formation of anti-inflammatory agents. These
effects allow to quickly and significantly limit the severe symptoms of acute inflammation and pain. However, at the same time, NSAIDs suppress the
sanogenetic mechanism of inflammation. Absence of correction of pathogenetic mechanisms of inflammation can lead to chronic inflammation and
development of its complications (cicatricial changes, adhesions, contractures, etc.). Also, nonselectivity of NSAIDs contributes to the development of
known side effects. And inhibitors of cyclooxygenase 2, as it became known, with excess daily therapeutic dose also cause serious side effects. New
possibilities for solving this problem have already been demonstrated by the bioregulatory approach and the complex bioregulatory medicines (BRMs)
created on its principles.
Conclusions: The complex bioregulatory action of the medicine Traumeel S allows to control and optimize the course of the inflammatory process wherever
it is located and of any form. Its use contributes to the full completion of inflammation with the recovery of the structure and function of the tissue,
reduces the risk of complications and chronic inflammation. Such characteristics, combined with good tolerability (absence of side effects characteristic
to NSAIDs) make Traumeel S a simple and reliable assistant to a doctor of any specialty in the treatment of inflammatory diseases of different localization

Katerenchuk, I. P

Popovich, S. V

Background: In the treatment of inflammation, the action of widely used non-steroidal anti-inflammatory drugs (NSAIDs) is directed mainly to inhibit the synthesis of proinflammatory mediators, cell migration and proliferation, as well as to stimulate the formation of anti-inflammatory agents. These effects allow to quickly and significantly limit the severe symptoms of acute inflammation and pain. However, at the same time, NSAIDs suppress the sanogenetic mechanism of inflammation. Absence of correction of pathogenetic mechanisms of inflammation can lead to chronic inflammation and development of its complications (cicatricial changes, adhesions, contractures, etc.). Also, nonselectivity of NSAIDs contributes to the development of known side effects. And inhibitors of cyclooxygenase 2, as it became known, with excess daily therapeutic dose also cause serious side effects. New possibilities for solving this problem have already been demonstrated by the bioregulatory approach and the complex bioregulatory medicines (BRMs) created on its principles. Conclusions: The complex bioregulatory action of the medicine Traumeel S allows to control and optimize the course of the inflammatory process wherever it is located and of any form. Its use contributes to the full completion of inflammation with the recovery of the structure and function of the tissue, reduces the risk of complications and chronic inflammation. Such characteristics, combined with good tolerability (absence of side effects characteristic to NSAIDs) make Traumeel S a simple and reliable assistant to a doctor of any specialty in the treatment of inflammatory diseases of different localization

S. V. Popovich

I. P. Katerenchuk

Directory of Open Access Journals

review articles The Moldovan Medical Journal, April 2017, Vol. 60, No 2IntroductionAcute inflammation is a protective reaction of the body to infection, traumatic, postischemic, toxic, autoimmune and other affection. Its main goal is the localization of this process with the further restoration of the damaged tissue structure and its function [3]. In the treatment of inflammation, the action of widely used non-steroidal anti-inflammatory drugs (NSAIDs) is directed mainly to inhibit the synthesis of pro-inflammatory mediators, cell migration and proliferation, as well as to stimulate the formation of anti-inflammatory agents. These effects allow to quickly and significantly limit the severe symptoms of acute inflammation and pain. However, at the same time, NSAIDs suppress the sanogenetic mechanism of inflammation. Absence of correction of pathogenetic mecha-nisms of inflammation can lead to chronic inflammation and development of its complications (cicatricial changes, adhe-sions, contractures, etc.). Also, nonselectivity of NSAIDs con-Traumeel S – bioregulatory approach in the treatment of inflammation*Popovich S. V.1, Katerenchuk I. P.21Department of Research, Ukrainian Academy of Biological Medicine, Kiev, Ukraine2Department of Internal Medicine, Ukrainian Medical Dental Academy, Poltava, Ukraine*Corresponding authors: popovich@cascade-medical.com.ua.  Received March 03, 2017; accepted April 14, 2017AbstractBackground: In the treatment of inflammation, the action of widely used non-steroidal anti-inflammatory drugs (NSAIDs) is directed mainly to inhibit the synthesis of proinflammatory mediators, cell migration and proliferation, as well as to stimulate the formation of anti-inflammatory agents. These effects allow to quickly and significantly limit the severe symptoms of acute inflammation and pain. However, at the same time, NSAIDs suppress the sanogenetic mechanism of inflammation. Absence of correction of pathogenetic mechanisms of inflammation can lead to chronic inflammation and development of its complications (cicatricial changes, adhesions, contractures, etc.). Also, nonselectivity of NSAIDs contributes to the development of known side effects. And inhibitors of cyclooxygenase 2, as it became known, with excess daily therapeutic dose also cause serious side effects.  New possibilities for solving this problem have already been demonstrated by the bioregulatory approach and the complex bioregulatory medicines (BRMs) created on its principles.Conclusions: The complex bioregulatory action of the medicine Traumeel S allows to control and optimize the course of the inflammatory process wherever it is located and of any form. Its use contributes to the full completion of inflammation with the recovery of the structure and function of the tissue, reduces the risk of complications and chronic inflammation. Such characteristics, combined with good tolerability (absence of side effects characteristic to NSAIDs) make Traumeel S a simple and reliable assistant to a doctor of any specialty in the treatment of inflammatory diseases of different localization.Key words: Traumeel S, bioregulatory approach, inflammation.tributes to the development of known side effects. And in-hibitors of cyclooxygenase 2, as it became known, with excess daily therapeutic dose also cause serious side effects [1].New possibilities for solving this problem have already been demonstrated by the bioregulatory approach and the complex bioregulatory medicines (BRMs) created on its prin-ciples. Old name – antihomotoxic medications (AHTM). Their peculiarity is the effect of ultra-small doses of compo-nents of vegetable and mineral origin that contribute to the activation of detoxification and the restoration of self-regu-lation processes, including in relation to the course of the in-flammatory process.Therewith, they do not suppress the natural protective and detoxifying mechanisms of the body [3, 9, 10, 17].Among the BRMs, the BRM Traumeel S (injectable solu-tion, ointment) showed great opportunities in the therapy of inflammatory diseases [2, 9–11, 13, 14].Fig. 1.  Spiral-stage of inflammation – components.DOI: 10.5281/zenodo.1051099UDC: 615.276:616-0024546review articlesThe Moldovan Medical Journal, April 2017, Vol. 60, No 2review articles The Moldovan Medical Journal, April 2017, Vol. 60, No 2Main pharmacological actions of Traumeel S: anti-inflam-matory (not suppression of inflammation, but its optimiza-tion only), antiexudative, regenerating, analgesic, immuno-correcting. These properties are provided by 14 components of plant and mineral origin in ultra-small (homeopathic) doses (fig. 1).The effectiveness of Traumeel S in inflammatory diseases is confirmed by many clinical studies conducted in Germany, Ukraine and other countries [1–17].Traumeel S in diseases of ENT organsTraumeel S has proven itself in the complex therapy of rhinosinusitis, otitis, tonsillitis, nasopharyngitis, both in their independent treatment and associated with the acute respi-ratory viral infection (ARVI), in the prevention of bacterial complications of ARVI [1-5, 7, 8, 12, 13].Peresadin N.A. and Dyachenko T. of the Lugansk State Medical University compared the indicators of cellular and humoral immunity in children with the prescription of con-ventional treatment and therapy of BRM / AHTM. It was con-cluded that Traumeel S, in combination with other BRMs has, when used step-by-step, a clinically beneficial effect: the num-ber of episodes of ARVI decreased 1.5-2 times, the manifesta-tions of intoxication, headache and fever decreased; they were significantly less expressed compared with the cough control group, running nose, chest pain, sore throat. The course use of BRMs outside the aggravation period for 1-4 years indicates the potentiating and protective adaptation action of Traumeel S and other AHTMs [5, 11, 12].Specialists from Belarus (Nikolaev V. V., Sakovich A. R., 1999) investigated the use of complex AHTMs in the treat-ment of acute purulent sinusitis.The results of treatment of patients with sinusitis using the complex of BRMs (Traumeel S, etc.) and treated with classi-cal therapy (antibiotics, antihistamines, vasoconstrictors, vi-tamins) were compared. The study shows that the treatment scheme for acute purulent maxillary sinusitis using BRMs is not inferior in effectiveness to conventional treatment. At the same time, a faster regression of the thermosymmetry indict-ors of the nasal mucosa, normalization of the pH of the nasal secretion associated with the decrease in the number of punc-tures in the group of patients receiving BMRs, indicates its undeniable advantages [15].Traumeel S in pulmonologyPolish colleagues demonstrated that the use of a single Traumeel S ampoule once a week in patients with corticoste-roid-dependent bronchial asthma allows lowering the daily dose of corticosteroids (triamcinolone) after five months from 4.6 to 2.6 mg, and in some patients even give up it.It is noted that the use of Traumeel S leads to an improve-ment in the overall clinical condition of patients, an increase in muscle strength, and also contributes to the reduction of complications associated with prolonged corticosteroid the-rapy [11].Traumeel S in nephrologic diseasesIn the campus of Uzhhorod State University (Kovalchuk I.A. et al., 1999), the efficacy of BMRs in the treatment of pa-tients with chronic pyelonephritis - Traumeel S, etc. was stud-ied. In the main group, the BMR was used along with etio-tropic drugs (antibiotics). As control was an identical group of patients who received treatment according to the standard method with allopathic drugs only. In patients of the main group, subjective improvement of the condition occurred much earlier, the laboratory indicators were faster than in the control group.No signs of toxicity, intolerance, side effects of use of AHTM were observed [16].Traumeel S, practical recommendationsThe most informative indicator describing the presence and intensity of the inflammatory process is the concentra-tion of the C-reactive protein (CRP) of blood serum. The in-crease in the level of CRP up to 3-7 mg / l already indicates local inflammation and serves as a criterion for the prescrip-tion of BMR Traumeel S. The criterion for stopping to receive Traumeel S is a decrease in the level of CRP below 3 mg / l [6].The studies showed there has been an increase in the ef-fectiveness of therapy for inflammation with the combina-tion of BMR Traumeel S injections with the local (ointment) form. During the acute period, along with the course of in-jections, it is recommended to apply locally ointment [2, 13, 14] (table 1).Table 1Recommendations for the dosage of Traumeel S when combined with several dosage formsAcute and subacute periodCompletion of treatment(2-4 weeks or more)Basic BMR in case of inflammation (CRP level 3-7 mg/l) Traumeel S 2,2 ml (1 amp) i/m, s/c, i/c daily No 3-5 2,2 ml (1 amp) i/m, s/c, i/c 2-3  times (up to decrease of CRP below 3 mg / l)Ointment: easily to rub in/ apply under the bandage / apply on the affected area: on the 1st day – 5-6 times, then 3 times / day Ointment: easily to rub in/ apply 2-3 times / day, incl. with mas-sage or injected with phonophoresis No 10 (daily)4748review articlesThe Moldovan Medical Journal, April 2017, Vol. 60, No 2ConclusionsThe complex bioregulatory action of the medicine Trau-meel S allows to control and optimize the course of the in-flammatory process wherever it is located and of any form. Its use contributes to the full completion of inflammation with the recovery of the structure and function of the tissue, reduc-es the risk of complications and chronic inflammation. Such characteristics, combined with good tolerability (absence of side effects characteristic to NSAIDs) make Traumeel S a simple and reliable assistant to a doctor of any specialty in the treatment of inflammatory diseases of different localization.References1. Chursina T.YA., Mikhalev K.A. Allopaticheskaya i antigomotoksi-cheskaya terapiya ostrogo vospaleniya: al’ternativnyye ili vzaimodo-polnyayushchiye puti [Allopathic and antihomotoxic therapy of acute inflammation: alternative or complementary ways]. Biologicheskaya terapiya [Biological Therapy]. 2006; 1:17-21. 2. Popovich S.V. Klinicheskiy obraz preparata Traumeel S. [Clinical im-age of the medicine Traumeel S]. Biologicheskaya terapiya [Biological Therapy]. 2006; 1:22-23. 3. Nikonenko A.G. Sovremennyye predstavleniya o mekhanizmakh regulyatsii vospalitel’nogo protsessa [Modern ideas about the mecha-nisms of inflammatory process regulation]. Biologicheskaya terapiya [Biological Therapy]. 2006; 1:11-15.4. Katerenchuk I.P., Chernomorets P.M., Klimenko V.G. Patogenetiches-kiye mekhanizmy razvitiya khronicheskogo vospaleniya i klyuchevyye aspekty yego antigomotoksicheskoy terapii [Pathogenetic mechanisms of development of chronic inflammation and key aspects of its anti-homotoxic therapy]. Biologicheskaya terapiya [Biological Therapy]. 2007; 1:4-14.5. Peresadin N.A., D’yachenko T.V. Kompleksnoye lecheniye i reabili-tatsiya patsiyentov s khronicheskimi zabolevaniyami LOR-organov i dykhatel’noy sistemy: sovremennyye metodologicheskiye aspekty ispol’zovaniya antigomotoksicheskikh sredstv u chasto boleyushchikh lits [Complex treatment and rehabilitation of patients with chronic diseases of ENT organs and the respiratory system: modern method-ological aspects of the use of antihomotoxic drugs in often ill persons]. Biologicheskaya terapiya [Biological Therapy]. 2004; 1:24-27.6. Pashchenko V.N., Girin S.V. Diagnosticheskaya rol’ S-reaktivnogo belka v sovremennoy klinicheskoy praktike [Diagnostic role of C-reactive protein in modern clinical practice]. Biologicheskaya Terapiya [Bio-logical Therapy]. 2010; 1:10-14.7. Kireyeva T.V., Sutyrina I.G., Ginkota L.V. Primeneniye antigomotok-sicheskikh preparatov v lechenii ostrykh respiratornykh virusnykh infektsiy [The use of antihomotoxic drugs in the treatment of acute respiratory viral infections].  Materialy Mezhdunarodnogo nauchno-prakticheskogo simpoziuma “Antigomotoksicheskaya terapiya ostrykh vospalitel’nykh zabolevaniy” [Materials of the International Scientific and Practical Symposium “Antihomotoxic Therapy of Acute Inflam-matory Diseases”]. 2006; 46-47.8. Khayne KH., Shmolts M.V. Immunologicheskaya vspomogatel’naya reaktsiya, vyzyvayemaya rastitel’nymi ekstraktami, soderzhashchimisya v antigomotoksicheskikh preparatakh [Immunological auxiliary reac-tion caused by plant extracts contained in antihomotoxic preparations]. Biologicheskaya meditsina [Biological medicine]. 1998; 2: 9-11.9. Khayne KH. Znacheniye antigomotoksicheskoy terapii v regulyatornoy meditsine [The value of antihomotoxic therapy in regulatory medi-cine]. Biologicheskaya meditsina [Biological medicine]. 2004; 2: 4-9.10. Van Brandt B., Khayne KH. Regulyatornaya blokada: opredeleniye, znacheniye i terapiya [Regulatory blockade: definition, significance and therapy]. Biologicheskaya meditsina [Biological medicine]. 2006; 4-5.11. Myuller-Lobnits K., Getel D. Klinicheskaya effektivnost kompleksnogo gomeopaticheskogo preparata Traumeel S i yego komponentov [Clini-cal efficacy of the complex homeopathic preparation Traumeel S and its components]. Biologicheskaya meditsina [Biological medicine]. 2013; 1: 13-27.12. Kramarev S.A., Palatna L.O., Shamugiya B.K. Al’ternativní metodi líkuvannya ta profílaktiki gripu ta GRVÍ u dítey [Alternative methods of treatment and prevention of influenza and acute respiratory viral infections in children]. Metodichní rekomendatsíí MOZ Ukraini [Guidelines of Ministry of Health of Ukraine]. 2006; 40.13. Shamugiya B.K., Timoshkov M.V. Vozmozhnosti preparata Traumeel S v terapii vospaleniya [Possibilities of Traumeel S in the treatment of inflammation]. Mistetstvo líkuvannya [Therapy Art]. 2013; 2-3 (98-99): 44-49.14. Byolohyshe Khaylmyttel Kheel HmbKH. Monohrafyya po preparatu Traumeel S [Biologische Heilmittel Heel GmbH: Monographie über das Medikament Traumeel S]. Per. s angl. M. Arnebiya [Trans. from English by M. Arnebyya]. 2011; 53.15. Nikolayev V.V.; Sakovich A.R. Kompleksnyye antigomotoksicheskiye preparaty v lechenii ostrykh gnoynykh sinusitov [Complex antihomo-toxic drugs in the treatment of acute purulent sinusitis]. Biologiches-kaya Meditsina [Biological medicine]. 1999; 2: 47-48.16. Koval’chuk I.A., Strizhak V.V., Shkoda-Ulyanova N.V. Opyt ispol’zovaniya kompleksnykh antigomotoksicheskikh preparatov Traumeel S, Echinacea compositum S i Lymphomyosot dlya lecheniya bol’nykh s khronicheskim piyelonefritom [Experience in the use of complex antihomotoxic drugs Traumeel S, Echinacea compositum S and Lymphomyosot for the treatment of patients with chronic pyelo-nephritis]. Biologicheskaya terapiya [Biological Therapy]. 1999; 3:6-8.17. Klimenko V.G. Osnovnyye polozheniya patogeneticheskogo bioregu-lyatsionnogo podkhoda v obshchey terapevticheskoy praktike [The main provisions of the pathogenetic bioregulatory approach in general therapeutic practice]. Biologicheskaya terapiya [Biological Therapy]. 2013; 1: 8-11.

Traumeel S – bioregulatory approach in the treatment of inflammation

Background: In the treatment of inflammation, the action of widely used non-steroidal anti-inflammatory drugs (NSAIDs) is directed mainly to inhibitthe synthesis of proinflammatory mediators, cell migration and proliferation, as well as to stimulate the formation of anti-inflammatory agents. Theseeffects allow to quickly and significantly limit the severe symptoms of acute inflammation and pain. However, at the same time, NSAIDs suppress thesanogenetic mechanism of inflammation. Absence of correction of pathogenetic mechanisms of inflammation can lead to chronic inflammation anddevelopment of its complications (cicatricial changes, adhesions, contractures, etc.). Also, nonselectivity of NSAIDs contributes to the development ofknown side effects. And inhibitors of cyclooxygenase 2, as it became known, with excess daily therapeutic dose also cause serious side effects. Newpossibilities for solving this problem have already been demonstrated by the bioregulatory approach and the complex bioregulatory medicines (BRMs)created on its principles.

Conclusions: The complex bioregulatory action of the medicine Traumeel S allows to control and optimize the course of the inflammatory process whereverit is located and of any form. Its use contributes to the full completion of inflammation with the recovery of the structure and function of the tissue,reduces the risk of complications and chronic inflammation. Such characteristics, combined with good tolerability (absence of side effects characteristicto NSAIDs) make Traumeel S a simple and reliable assistant to a doctor of any specialty in the treatment of inflammatory diseases of different localization

Popovich, S. V.

Katerenchuk, I. P.

NEUROSURGERY ENTHUSIASTIC WOMEN SOCIETY

ZENODO

Institutional Repository in Medical Sciences of Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova

REVIEW ARTICLES The Moldovan Medical Journal, April 2017, Vol. 60, No 2IntroductionAcute inflammation is a protective reaction of the body to infection, traumatic, postischemic, toxic, autoimmune and other affection. Its main goal is the localization of this process with the further restoration of the damaged tissue structure and its function [3]. In the treatment of inflammation, the action of widely used non-steroidal anti-inflammatory drugs (NSAIDs) is directed mainly to inhibit the synthesis of pro-inflammatory mediators, cell migration and proliferation, as well as to stimulate the formation of anti-inflammatory agents. These effects allow to quickly and significantly limit the severe symptoms of acute inflammation and pain. However, at the same time, NSAIDs suppress the sanogenetic mechanism of inflammation. Absence of correction of pathogenetic mecha-nisms of inflammation can lead to chronic inflammation and development of its complications (cicatricial changes, adhe-sions, contractures, etc.). Also, nonselectivity of NSAIDs con-Traumeel S – bioregulatory approach in the treatment of inflammation*Popovich S. V.1, Katerenchuk I. P.21Department of Research, Ukrainian Academy of Biological Medicine, Kiev, Ukraine2Department of Internal Medicine, Ukrainian Medical Dental Academy, Poltava, Ukraine*Corresponding authors: .  Received March 03, 2017; accepted April 14, 2017AbstractBackground: In the treatment of inflammation, the action of widely used non-steroidal anti-inflammatory drugs (NSAIDs) is directed mainly to inhibit the synthesis of proinflammatory mediators, cell migration and proliferation, as well as to stimulate the formation of anti-inflammatory agents. These effects allow to quickly and significantly limit the severe symptoms of acute inflammation and pain. However, at the same time, NSAIDs suppress the sanogenetic mechanism of inflammation. Absence of correction of pathogenetic mechanisms of inflammation can lead to chronic inflammation and development of its complications (cicatricial changes, adhesions, contractures, etc.). Also, nonselectivity of NSAIDs contributes to the development of known side effects. And inhibitors of cyclooxygenase 2, as it became known, with excess daily therapeutic dose also cause serious side effects.  New possibilities for solving this problem have already been demonstrated by the bioregulatory approach and the complex bioregulatory medicines (BRMs) created on its principles.Conclusions: The complex bioregulatory action of the medicine Traumeel S allows to control and optimize the course of the inflammatory process wherever it is located and of any form. Its use contributes to the full completion of inflammation with the recovery of the structure and function of the tissue, reduces the risk of complications and chronic inflammation. Such characteristics, combined with good tolerability (absence of side effects characteristic to NSAIDs) make Traumeel S a simple and reliable assistant to a doctor of any specialty in the treatment of inflammatory diseases of different localization.Key words: Traumeel S, bioregulatory approach, inflammation.tributes to the development of known side effects. And in-hibitors of cyclooxygenase 2, as it became known, with excess daily therapeutic dose also cause serious side effects [1].New possibilities for solving this problem have already been demonstrated by the bioregulatory approach and the complex bioregulatory medicines (BRMs) created on its prin-ciples. Old name – antihomotoxic medications (AHTM). Their peculiarity is the effect of ultra-small doses of compo-nents of vegetable and mineral origin that contribute to the activation of detoxification and the restoration of self-regu-lation processes, including in relation to the course of the in-flammatory process.Therewith, they do not suppress the natural protective and detoxifying mechanisms of the body [3, 9, 10, 17].Among the BRMs, the BRM Traumeel S (injectable solu-tion, ointment) showed great opportunities in the therapy of inflammatory diseases [2, 9–11, 13, 14].Fig. 1.  Spiral-stage of inflammation – components.DOI: 10.5281/zenodo.1051099UDC: 615.276:616-0024546REVIEW ARTICLESThe Moldovan Medical Journal, April 2017, Vol. 60, No 2REVIEW ARTICLES The Moldovan Medical Journal, April 2017, Vol. 60, No 2Main pharmacological actions of Traumeel S: anti-inflam-matory (not suppression of inflammation, but its optimiza-tion only), antiexudative, regenerating, analgesic, immuno-correcting. These properties are provided by 14 components of plant and mineral origin in ultra-small (homeopathic) doses (fig. 1).The effectiveness of Traumeel S in inflammatory diseases is confirmed by many clinical studies conducted in Germany, Ukraine and other countries [1–17].Traumeel S in diseases of ENT organsTraumeel S has proven itself in the complex therapy of rhinosinusitis, otitis, tonsillitis, nasopharyngitis, both in their independent treatment and associated with the acute respi-ratory viral infection (ARVI), in the prevention of bacterial complications of ARVI [1-5, 7, 8, 12, 13].Peresadin N.A. and Dyachenko T. of the Lugansk State Medical University compared the indicators of cellular and humoral immunity in children with the prescription of con-ventional treatment and therapy of BRM / AHTM. It was con-cluded that Traumeel S, in combination with other BRMs has, when used step-by-step, a clinically beneficial effect: the num-ber of episodes of ARVI decreased 1.5-2 times, the manifesta-tions of intoxication, headache and fever decreased; they were significantly less expressed compared with the cough control group, running nose, chest pain, sore throat. The course use of BRMs outside the aggravation period for 1-4 years indicates the potentiating and protective adaptation action of Traumeel S and other AHTMs [5, 11, 12].Specialists from Belarus (Nikolaev V. V., Sakovich A. R., 1999) investigated the use of complex AHTMs in the treat-ment of acute purulent sinusitis.The results of treatment of patients with sinusitis using the complex of BRMs (Traumeel S, etc.) and treated with classi-cal therapy (antibiotics, antihistamines, vasoconstrictors, vi-tamins) were compared. The study shows that the treatment scheme for acute purulent maxillary sinusitis using BRMs is not inferior in effectiveness to conventional treatment. At the same time, a faster regression of the thermosymmetry indict-ors of the nasal mucosa, normalization of the pH of the nasal secretion associated with the decrease in the number of punc-tures in the group of patients receiving BMRs, indicates its undeniable advantages [15].Traumeel S in pulmonologyPolish colleagues demonstrated that the use of a single Traumeel S ampoule once a week in patients with corticoste-roid-dependent bronchial asthma allows lowering the daily dose of corticosteroids (triamcinolone) after five months from 4.6 to 2.6 mg, and in some patients even give up it.It is noted that the use of Traumeel S leads to an improve-ment in the overall clinical condition of patients, an increase in muscle strength, and also contributes to the reduction of complications associated with prolonged corticosteroid the-rapy [11].Traumeel S in nephrologic diseasesIn the campus of Uzhhorod State University (Kovalchuk I.A. et al., 1999), the efficacy of BMRs in the treatment of pa-tients with chronic pyelonephritis - Traumeel S, etc. was stud-ied. In the main group, the BMR was used along with etio-tropic drugs (antibiotics). As control was an identical group of patients who received treatment according to the standard method with allopathic drugs only. In patients of the main group, subjective improvement of the condition occurred much earlier, the laboratory indicators were faster than in the control group.No signs of toxicity, intolerance, side effects of use of AHTM were observed [16].Traumeel S, practical recommendationsThe most informative indicator describing the presence and intensity of the inflammatory process is the concentra-tion of the C-reactive protein (CRP) of blood serum. The in-crease in the level of CRP up to 3-7 mg / l already indicates local inflammation and serves as a criterion for the prescrip-tion of BMR Traumeel S. The criterion for stopping to receive Traumeel S is a decrease in the level of CRP below 3 mg / l [6].The studies showed there has been an increase in the ef-fectiveness of therapy for inflammation with the combina-tion of BMR Traumeel S injections with the local (ointment) form. During the acute period, along with the course of in-jections, it is recommended to apply locally ointment [2, 13, 14] (table 1).Table 1Recommendations for the dosage of Traumeel S when combined with several dosage formsAcute and subacute periodCompletion of treatment(2-4 weeks or more)Basic BMR in case of inflammation (CRP level 3-7 mg/l) Traumeel S 2,2 ml (1 amp) i/m, s/c, i/c daily No 3-5 2,2 ml (1 amp) i/m, s/c, i/c 2-3  times (up to decrease of CRP below 3 mg / l)Ointment: easily to rub in/ apply under the bandage / apply on the affected area: on the 1st day – 5-6 times, then 3 times / day Ointment: easily to rub in/ apply 2-3 times / day, incl. with mas-sage or injected with phonophoresis No 10 (daily)4748REVIEW ARTICLESThe Moldovan Medical Journal, April 2017, Vol. 60, No 2ConclusionsThe complex bioregulatory action of the medicine Trau-meel S allows to control and optimize the course of the in-flammatory process wherever it is located and of any form. Its use contributes to the full completion of inflammation with the recovery of the structure and function of the tissue, reduc-es the risk of complications and chronic inflammation. Such characteristics, combined with good tolerability (absence of side effects characteristic to NSAIDs) make Traumeel S a simple and reliable assistant to a doctor of any specialty in the treatment of inflammatory diseases of different localization.References1. Chursina T.YA., Mikhalev K.A. Allopaticheskaya i antigomotoksi-cheskaya terapiya ostrogo vospaleniya: al’ternativnyye ili vzaimodo-polnyayushchiye puti [Allopathic and antihomotoxic therapy of acute inflammation: alternative or complementary ways]. Biologicheskaya terapiya [Biological Therapy]. 2006; 1:17-21. 2. Popovich S.V. Klinicheskiy obraz preparata Traumeel S. [Clinical im-age of the medicine Traumeel S]. Biologicheskaya terapiya [Biological Therapy]. 2006; 1:22-23. 3. Nikonenko A.G. Sovremennyye predstavleniya o mekhanizmakh regulyatsii vospalitel’nogo protsessa [Modern ideas about the mecha-nisms of inflammatory process regulation]. Biologicheskaya terapiya [Biological Therapy]. 2006; 1:11-15.4. Katerenchuk I.P., Chernomorets P.M., Klimenko V.G. Patogenetiches-kiye mekhanizmy razvitiya khronicheskogo vospaleniya i klyuchevyye aspekty yego antigomotoksicheskoy terapii [Pathogenetic mechanisms of development of chronic inflammation and key aspects of its anti-homotoxic therapy]. Biologicheskaya terapiya [Biological Therapy]. 2007; 1:4-14.5. Peresadin N.A., D’yachenko T.V. Kompleksnoye lecheniye i reabili-tatsiya patsiyentov s khronicheskimi zabolevaniyami LOR-organov i dykhatel’noy sistemy: sovremennyye metodologicheskiye aspekty ispol’zovaniya antigomotoksicheskikh sredstv u chasto boleyushchikh lits [Complex treatment and rehabilitation of patients with chronic diseases of ENT organs and the respiratory system: modern method-ological aspects of the use of antihomotoxic drugs in often ill persons]. Biologicheskaya terapiya [Biological Therapy]. 2004; 1:24-27.6. Pashchenko V.N., Girin S.V. Diagnosticheskaya rol’ S-reaktivnogo belka v sovremennoy klinicheskoy praktike [Diagnostic role of C-reactive protein in modern clinical practice]. Biologicheskaya Terapiya [Bio-logical Therapy]. 2010; 1:10-14.7. Kireyeva T.V., Sutyrina I.G., Ginkota L.V. Primeneniye antigomotok-sicheskikh preparatov v lechenii ostrykh respiratornykh virusnykh infektsiy [The use of antihomotoxic drugs in the treatment of acute respiratory viral infections].  Materialy Mezhdunarodnogo nauchno-prakticheskogo simpoziuma “Antigomotoksicheskaya terapiya ostrykh vospalitel’nykh zabolevaniy” [Materials of the International Scientific and Practical Symposium “Antihomotoxic Therapy of Acute Inflam-matory Diseases”]. 2006; 46-47.8. Khayne KH., Shmolts M.V. Immunologicheskaya vspomogatel’naya reaktsiya, vyzyvayemaya rastitel’nymi ekstraktami, soderzhashchimisya v antigomotoksicheskikh preparatakh [Immunological auxiliary reac-tion caused by plant extracts contained in antihomotoxic preparations]. Biologicheskaya meditsina [Biological medicine]. 1998; 2: 9-11.9. Khayne KH. Znacheniye antigomotoksicheskoy terapii v regulyatornoy meditsine [The value of antihomotoxic therapy in regulatory medi-cine]. Biologicheskaya meditsina [Biological medicine]. 2004; 2: 4-9.10. Van Brandt B., Khayne KH. Regulyatornaya blokada: opredeleniye, znacheniye i terapiya [Regulatory blockade: definition, significance and therapy]. Biologicheskaya meditsina [Biological medicine]. 2006; 4-5.11. Myuller-Lobnits K., Getel D. Klinicheskaya effektivnost kompleksnogo gomeopaticheskogo preparata Traumeel S i yego komponentov [Clini-cal efficacy of the complex homeopathic preparation Traumeel S and its components]. Biologicheskaya meditsina [Biological medicine]. 2013; 1: 13-27.12. Kramarev S.A., Palatna L.O., Shamugiya B.K. Al’ternativní metodi líkuvannya ta profílaktiki gripu ta GRVÍ u dítey [Alternative methods of treatment and prevention of influenza and acute respiratory viral infections in children]. Metodichní rekomendatsíí MOZ Ukraini [Guidelines of Ministry of Health of Ukraine]. 2006; 40.13. Shamugiya B.K., Timoshkov M.V. Vozmozhnosti preparata Traumeel S v terapii vospaleniya [Possibilities of Traumeel S in the treatment of inflammation]. Mistetstvo líkuvannya [Therapy Art]. 2013; 2-3 (98-99): 44-49.14. Byolohyshe Khaylmyttel Kheel HmbKH. Monohrafyya po preparatu Traumeel S [Biologische Heilmittel Heel GmbH: Monographie über das Medikament Traumeel S]. Per. s angl. M. Arnebiya [Trans. from English by M. Arnebyya]. 2011; 53.15. Nikolayev V.V.; Sakovich A.R. Kompleksnyye antigomotoksicheskiye preparaty v lechenii ostrykh gnoynykh sinusitov [Complex antihomo-toxic drugs in the treatment of acute purulent sinusitis]. Biologiches-kaya Meditsina [Biological medicine]. 1999; 2: 47-48.16. Koval’chuk I.A., Strizhak V.V., Shkoda-Ulyanova N.V. Opyt ispol’zovaniya kompleksnykh antigomotoksicheskikh preparatov Traumeel S, Echinacea compositum S i Lymphomyosot dlya lecheniya bol’nykh s khronicheskim piyelonefritom [Experience in the use of complex antihomotoxic drugs Traumeel S, Echinacea compositum S and Lymphomyosot for the treatment of patients with chronic pyelo-nephritis]. Biologicheskaya terapiya [Biological Therapy]. 1999; 3:6-8.17. Klimenko V.G. Osnovnyye polozheniya patogeneticheskogo bioregu-lyatsionnogo podkhoda v obshchey terapevticheskoy praktike [The main provisions of the pathogenetic bioregulatory approach in general therapeutic practice]. Biologicheskaya terapiya [Biological Therapy]. 2013; 1: 8-11.

http://moldmedjournal.md/wp-content/uploads/2018/10/moldmedjournal-2017-602-popovich-full-article.pdf

Traumeel S – bioregulatory approach in the treatment of inflammation

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals

NEUROSURGERY ENTHUSIASTIC WOMEN SOCIETY

ZENODO

Institutional Repository in Medical Sciences of Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova